Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Omeros Is Sinking Further Today

By Cory Renauer – Oct 18, 2021 at 11:24AM

Key Points

  • The FDA sent Omeros a complete response letter regarding its application for narsoplimab as a treatment for thrombotic microangiopathy.
  • Earlier this month, Omeros told investors the FDA had identified deficiencies that prevented the discussion of labeling and post-marketing requirements.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bad news the company received today from the FDA surprised investors more than it probably should have.

What happened

Omeros (OMER 2.11%) stock is falling hard again for the second time this month. A complete response letter from the FDA for narsoplimab is the culprit today. Disappointed investors have pushed the stock 23.7% lower as of 11:43 a.m. EDT on Monday.

So what 

Omeros is a commercial-stage biopharmaceutical company that markets Omidria, a pupil-dilating drug used during eye surgery. Investors had a lot of hopes pinned to narsoplimab because Omidria sales rely on a tentative pass-through payment status that isn't very reliable.

An investment advisor showing a client why his stock price is falling.

Image source: Getty Images.

On Oct. 1, Omeros told investors that the FDA had identified deficiencies that precluded the discussion of labeling requirements. Investors had been hoping the FDA would request something simple, but that wasn't the case. The biotech stock is tumbling today because the agency asked for another trial.

Now what

Investors probably shouldn't be surprised the FDA expressed difficulty estimating the treatment effect of narsoplimab. Omeros submitted an application supported by a 28-patient, open-label study.

There are situations in which employing a control group for the sake of comparison isn't practical. Stem cell transplant-associated microangiopathy isn't one of them. This is a dangerous side effect of stem-cell transplants that thousands of Americans experience each year. 

Omeros has two more new drug candidates in clinical trials, OMS906 and OMS527. I wouldn't expect much from either of these. Both are potential first-in-class drugs the FDA cleared to begin clinical trials over a year ago, and neither is active at the moment. Despite plenty of time to move forward, the company hasn't registered a study for either candidate on the U.S. government's clinical trials database yet.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.